Unverified Drug Allergy Labels Before Surgery: Test Them or Work Around Them

Frank D., a 71-year-old man, has been walking with a cane for the better part of three years waiting for his right knee to get bad enough to justify surgery, and now that it finally has, he doesn't want anything delaying the total knee replacement his orthopedic surgeon has scheduled for six weeks from now. His chart carries three separate drug-allergy labels, none confirmed by any formal evaluation: penicillin, from a childhood rash he can't describe in any detail; sulfa, from stomach upset as a child after a course of an antibiotic his mother can no longer name; and codeine, listed as an allergy after a reaction that, on closer questioning, was nausea and vomiting rather than hives, swelling, or breathing trouble. He has no history of anaphylaxis to anything, no other chronic illness, and has taken ibuprofen and acetaminophen without issue for years. He retired from a career in commercial HVAC installation eight years ago and has spent much of that retirement, by his own account, more sedentary than he'd like because of the knee, and he has already lined up a neighbor to drive him to physical therapy appointments for the six weeks after surgery — the kind of practical groundwork that makes the idea of a delay, for any reason, particularly unwelcome to him.

His three labels matter directly to how his surgery gets covered: cefazolin, the standard, most effective surgical-site-infection prophylaxis for a joint replacement, is a beta-lactam his penicillin label would otherwise rule out, forcing a substitution to vancomycin or clindamycin instead. Blumenthal's 2018 cohort of more than 8,000 surgical patients found a penicillin-allergy label alone carried 50% increased odds of surgical-site infection — an effect its authors traced entirely to the second-line antibiotic the label triggers, not to anything about the patients themselves — not because vancomycin doesn't work, but because it works less well for this specific purpose and takes longer to infuse before incision. With six weeks before his surgery date, Frank has time most patients facing this exact question don't: enough to actually find out which, if any, of his three labels reflect a real allergy before the operating room has to work around an assumption instead of an answer. The timing constraint isn't trivial either: cefazolin's dosing window requires infusion beginning within roughly an hour before incision, while vancomycin needs to start infusing considerably earlier to avoid a histamine-mediated infusion reaction of its own — a scheduling wrinkle that adds real friction to OR timing on the day itself, independent of which drug ultimately proves more effective.

Ruth A., a 68-year-old woman, was brought to the emergency department eighteen hours ago with severe right-upper-quadrant pain, fever, and imaging showing acute cholecystitis with early signs of gallbladder wall necrosis — a presentation her surgical team considers unsafe to manage without an operation within the next several hours, not days. Her chart carries a single drug-allergy label, but a serious one: a documented intraoperative anaphylactic reaction to rocuronium during a hysterectomy eleven years ago, complete with the anesthesia record from that admission describing hypotension, bronchospasm, and a rash within minutes of induction, successfully treated in the operating room at the time. She has had no other surgeries since, no other drug reactions on record, and is otherwise in reasonable health for her age aside from well-controlled hypertension. She lives alone since her husband's death three years ago, and it was a scheduled phone call from her daughter, unanswered for several hours, that prompted a welfare check and ultimately got her to the emergency department before the infection progressed further — a stroke of ordinary luck her surgical team has noted matters little now except as a reminder of how narrow her margin already was before anesthesia's own question even entered the picture.

Neuromuscular blocking agents are broadly divided into two structural families — aminosteroids, which include rocuronium and vecuronium, and benzylisoquinoliniums, which include cisatracurium and atracurium — and IgE-mediated NMBA reactions often target a quaternary ammonium ion shared across both families rather than a feature unique to one, which is exactly why cross-reactivity, while generally lower between the two structural classes than within one, is never reliably zero without skin testing to confirm it. Ruth's reaction record describes a classic, severe, immediate hypersensitivity pattern, and eleven years of avoiding any further NMBA exposure has left it uninvestigated by the kind of testing that could tell her anesthesia team, with real confidence, which specific agent is actually safe — testing that, with surgery needed within hours, there is no time left to obtain. A rocuronium-free, entirely NMBA-free anesthetic is technically possible but carries its own real tradeoffs for a patient with active intra-abdominal infection, including a harder airway-management course without the muscle relaxation a blocking agent provides — which is precisely why the actual choice in front of her team isn't simply “avoid the drug that hurt her once,” but which specific alternative, if any, best balances a documented risk against an active, worsening infection.